Core Insights - Healthcare Realty Trust (HR) reported a revenue of $298.98 million for the quarter ended March 2025, reflecting an 8.5% decline year-over-year and a surprise of -1.56% compared to the Zacks Consensus Estimate of $303.7 million [1] - The company's EPS was $0.39, a significant improvement from -$0.82 in the same quarter last year, aligning with the consensus estimate [1] Revenue Breakdown - Rental income was reported at $288.86 million, which is a 9.2% decrease year-over-year and below the three-analyst average estimate of $297.91 million [4] - Interest income came in at $3.73 million, down 17.8% from the previous year and below the average estimate of $4.68 million from two analysts [4] - Other operating revenues were $6.39 million, exceeding the average estimate of $5.35 million and showing a year-over-year increase of 52.5% [4] Stock Performance - Over the past month, shares of Healthcare Realty Trust have returned -7.8%, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Group 1 - Travere Therapeutics reported $81.73 million in revenue for Q1 2025, a year-over-year increase of 97.6% [1] - The EPS for the same period was -$0.47, improving from -$1.76 a year ago, with a surprise of +14.55% compared to the consensus estimate of -$0.55 [1] - The revenue exceeded the Zacks Consensus Estimate of $79.35 million, resulting in a surprise of +3.00% [1] Group 2 - Key metrics indicate that Travere's stock has returned +16% over the past month, while the Zacks S&P 500 composite has decreased by -0.7% [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance against the broader market in the near term [3] Group 3 - Revenue from Tiopronin products (Thiola) was $19.98 million, slightly below the average estimate of $20.90 million, representing a year-over-year change of -0.8% [4] - Total net product sales reached $75.86 million, exceeding the estimated $69.96 million [4] - Revenue from FILSPARI was $55.88 million, surpassing the average estimate of $49.31 million, with a year-over-year increase of +181.7% [4] - License and collaboration revenue was reported at $5.87 million, above the average estimate of $4.20 million, reflecting a year-over-year change of +322.4% [4]

Financial Performance - For the quarter ended March 2025, Live Nation reported revenue of $3.38 billion, down 11% year-over-year, and EPS of -$0.32 compared to -$0.53 in the same quarter last year [1] - The reported revenue was a surprise of -2.89% compared to the Zacks Consensus Estimate of $3.48 billion, while the EPS surprise was +5.88% against the consensus estimate of -$0.34 [1] Key Metrics - Estimated attendance for concerts totaled 22.31 million, below the average estimate of 23.37 million from five analysts [4] - Total fee-bearing tickets sold were 77.49 million, compared to the average estimate of 79.59 million [4] - Revenue from concerts was $2.48 billion, slightly below the estimated $2.51 billion, representing a year-over-year decline of -13.7% [4] - Revenue from sponsorship and advertising was $216.10 million, slightly below the estimate of $216.47 million, with a year-over-year increase of +2.3% [4] - Revenue from ticketing was $694.70 million, compared to the average estimate of $773.21 million, reflecting a year-over-year change of -3.9% [4] Stock Performance - Shares of Live Nation have returned -1.6% over the past month, while the Zacks S&P 500 composite changed by -0.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Glaukos reported $106.66 million in revenue for Q1 2025, a 24.6% year-over-year increase, with an EPS of -$0.22 compared to -$0.70 a year ago, exceeding the Zacks Consensus Estimate of $102.72 million by 3.84% [1] - The company achieved an EPS surprise of 33.33%, with the consensus EPS estimate being -$0.33 [1] Revenue Breakdown - U.S. revenues reached $75.07 million, surpassing the average estimate of $71.54 million, reflecting a 30.1% year-over-year increase [4] - International revenues totaled $31.59 million, slightly above the average estimate of $31.35 million, marking a 13.1% year-over-year increase [4] - Corneal Health revenues in the international market were $2.59 million, below the average estimate of $2.78 million, showing a decline of 4.1% year-over-year [4] - U.S. Corneal Health revenues were $15.94 million, exceeding the average estimate of $15.50 million, with a 1.5% year-over-year increase [4] - International Glaucoma revenues amounted to $29.01 million, surpassing the average estimate of $28.57 million, reflecting a 14.9% year-over-year increase [4] - U.S. Glaucoma revenues reached $59.13 million, exceeding the average estimate of $56.03 million, with a significant 40.8% year-over-year increase [4] - Total Corneal Health revenues were $18.53 million, slightly above the average estimate of $18.28 million, representing a 0.7% year-over-year increase [4] - Total Glaucoma revenues were $88.14 million, exceeding the average estimate of $84.60 million, reflecting a 31.1% year-over-year increase [4] Stock Performance - Glaukos shares have returned -5.8% over the past month, compared to the Zacks S&P 500 composite's -0.7% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]

Core Insights - Harley-Davidson reported a revenue of $1.08 billion for the quarter ended March 2025, reflecting a decline of 26.8% year-over-year and a surprise of -3.24% compared to the Zacks Consensus Estimate of $1.12 billion [1] - The earnings per share (EPS) was $1.07, down from $1.72 in the same quarter last year, with an EPS surprise of +33.75% against the consensus estimate of $0.80 [1] Financial Performance Metrics - Harley-Davidson's worldwide retail motorcycle sales totaled 31,010 units, falling short of the average estimate of 36,821 units [4] - Total worldwide motorcycle shipments were 38,601, compared to the average estimate of 40,365 [4] - Revenue from motorcycles and related products was $863.86 million, slightly above the average estimate of $861.54 million, but still down 29.3% year-over-year [4] - Revenue from licensing was reported at $3.06 million, significantly below the average estimate of $8.03 million, representing a year-over-year decline of 65.8% [4] - Revenue from Live Wire was $2.74 million, compared to the estimated $6.64 million, marking a 41.7% decrease year-over-year [4] - Apparel revenue was $57.32 million, below the average estimate of $63.92 million [4] - Parts & Accessories revenue was $143.43 million, compared to the average estimate of $163.70 million, reflecting a year-over-year decline of 13.7% [4] - Financial services revenue was $244.96 million, slightly below the average estimate of $249.71 million, with a year-over-year change of -1.5% [4] Stock Performance - Over the past month, Harley-Davidson shares have returned -12.4%, contrasting with the Zacks S&P 500 composite's -0.7% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]

Financial Performance - Shake Shack reported revenue of $320.9 million for the quarter ended March 2025, reflecting a year-over-year increase of 10.5% [1] - The EPS for the same period was $0.14, compared to $0.13 a year ago, indicating a slight improvement [1] - The reported revenue fell short of the Zacks Consensus Estimate of $327.76 million, resulting in a surprise of -2.09% [1] - The company experienced an EPS surprise of -12.50%, with the consensus EPS estimate being $0.16 [1] Key Metrics - Shake Shack's same-Shack sales growth was 0.2%, significantly below the 2.5% estimated by analysts [4] - The total number of licensed Shacks was 256, matching the average estimate [4] - Domestic company-operated Shack counts stood at 333, in line with analyst expectations [4] - System-wide Shack counts totaled 589, consistent with the average estimate [4] - International licensed Shack counts were 211, also matching the average estimate [4] - Domestic licensed Shack counts were 45, slightly below the average estimate of 46 [4] - Average weekly sales were $72, compared to the average estimate of $73.54 [4] - Revenue from licensing was $11.06 million, exceeding the average estimate of $10.84 million, representing a year-over-year change of +11.1% [4] - Revenue from Shack sales was $309.84 million, below the average estimate of $316.72 million, with a year-over-year change of +10.4% [4] - Shack system-wide sales reached $489.40 million, slightly below the estimated $495.03 million, but still reflecting a +10.4% change year-over-year [4] Stock Performance - Shake Shack shares have returned -8.3% over the past month, compared to the Zacks S&P 500 composite's -0.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Cheesecake Factory reported revenue of $927.2 million for the quarter ended March 2025, reflecting a 4% increase year-over-year [1] - The company's EPS was $0.93, up from $0.73 in the same quarter last year, exceeding the consensus estimate of $0.81 by 14.81% [1] - The revenue surpassed the Zacks Consensus Estimate of $925.55 million by 0.18% [1] Financial Performance Metrics - Comparable restaurant sales for The Cheesecake Factory were reported at 1%, slightly below the nine-analyst average estimate of 1.2% [4] - North Italia's comparable restaurant sales were down 1%, compared to the eight-analyst average estimate of 1.4% [4] - Total number of company-owned restaurants was 355, below the average estimate of 359 by eight analysts [4] Revenue Breakdown - Revenues from The Cheesecake Factory restaurants were $672.73 million, slightly below the estimated $673.38 million, representing a year-over-year increase of 0.7% [4] - Revenues from Other segments were $83.63 million, compared to the average estimate of $84.31 million, showing a year-over-year increase of 6.8% [4] - Revenues from Other FRC were $87.42 million, exceeding the average estimate of $86.99 million, with a year-over-year change of 17.8% [4] - Revenues from North Italia were $83.41 million, surpassing the estimated $81.63 million, reflecting a 17.7% increase year-over-year [4] Stock Performance - Cheesecake Factory shares have returned -2.4% over the past month, compared to a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Financial Performance - For the quarter ended March 2025, Sprouts Farmers (SFM) reported revenue of $2.24 billion, an increase of 18.7% year-over-year [1] - EPS for the quarter was $1.81, up from $1.12 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $2.2 billion, resulting in a surprise of +1.88% [1] - The company delivered an EPS surprise of +17.53%, with the consensus EPS estimate being $1.54 [1] Key Metrics - Comparable store sales growth was 11.7%, surpassing the average estimate of 10.7% based on four analysts [4] - The number of stores at the end of the period was 443, slightly below the four-analyst average estimate of 444 [4] - Three new stores were opened, compared to an average estimate of four by three analysts [4] - The number of stores at the beginning of the period was 440, matching the two-analyst average estimate [4] Stock Performance - Shares of Sprouts Farmers have returned +11% over the past month, while the Zacks S&P 500 composite experienced a -0.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential outperformance against the broader market in the near term [3]

Core Insights - Ionis Pharmaceuticals reported revenue of $132 million for the quarter ended March 2025, reflecting a year-over-year increase of 10.9% and surpassing the Zacks Consensus Estimate of $120.16 million by 9.86% [1] - The company's EPS was -$0.75, an improvement from -$0.98 in the same quarter last year, with an EPS surprise of 32.43% against a consensus estimate of -$1.11 [1] Revenue Breakdown - Commercial revenue from SPINRAZA royalties was $48 million, exceeding the average estimate of $43.02 million by nine analysts, marking a 26.3% increase year over year [4] - Total commercial revenue reached $76 million, surpassing the average estimate of $66.61 million based on eight analysts, representing a 28.8% year-over-year change [4] - Total research and development revenue was $56 million, compared to the average estimate of $50.44 million [4] - WAINUA royalties generated $9 million, slightly below the average estimate of $9.89 million [4] - Other commercial revenue from TEGSEDI and WAYLIVRA was $6 million, falling short of the average estimate of $6.93 million, indicating a 33.3% decline year over year [4] - Collaborative agreement revenue within research and development was $46 million, exceeding the average estimate of $37.10 million, but reflecting a 6.1% decrease year over year [4] Stock Performance - Ionis Pharmaceuticals' shares have returned +9.4% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

For the quarter ended March 2025, Littelfuse (LFUS) reported revenue of $554.31 million, up 3.5% over the same period last year. EPS came in at $2.19, compared to $1.76 in the year-ago quarter.The reported revenue represents a surprise of +2.71% over the Zacks Consensus Estimate of $539.67 million. With the consensus EPS estimate being $1.82, the EPS surprise was +20.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ex ...